Dr. Jason Samarasena, MD

Claim this profile

University of California Irvine

Studies Pancreatic Cyst
Studies Systemic Inflammatory Response Syndrome
2 reported clinical trials
4 drugs studied

Affiliated Hospitals

Image of trial facility.
University Of California, Irvine
Image of trial facility.
University Of California At Irvine Medical Center

Clinical Trials Jason Samarasena, MD is currently running

Image of trial facility.

EUS-FNA With/Without MFB

for Pancreatic Cysts

Pancreatic cystic lesions (PCLs) are a common incidental finding in cross sectional imaging (up to 27% on CT scan and 41% on MRI) and pose a management challenge to physicians. According to society guidelines, PCLs with specific features should prompt additional workup with endoscopic ultrasound (EUS) for cyst characterization as well as cyst sampling. This can help determine if the cyst is mucinous or non-mucinous which has implications for its malignant potential. Cyst fluid has traditionally been sampled using EUS with fine needle aspiration (EUS-FNA) and sent for fluid analysis and cytology. More recently, the adjunctive use of the through-the-scope micro forceps (Moray micro forceps, US Endoscopy, Mentor, OH) biopsy (EUS-MFB) has shown promise for diagnosis of PCLs. This technology utilizes a micro forceps through a 19-gauge needle to biopsy the cyst wall for histology, in addition to collecting cyst fluid for CEA level and cytology. More recently, the adjunctive use of the Moray® through the needle micro forceps biopsy (EUS-MFB) has shown promise for diagnosis of PCLs. This technology utilizes a micro forceps through a 19-gauge needle to biopsy the cyst wall for histology, in addition to collecting cyst fluid for CEA level and cytology. Only a few small retrospective reports have been published regarding the use of MFB. The results of this study will hopefully help increase diagnostic yield by obtaining a histopathologic diagnosis of these PCLs, and potentially affect practice patterns of gastroenterologists and the endoscopic community, specifically those physicians who perform EUS in these patients. Furthermore, the results will help determine whether there is reason to continue this line of research to obtain a definite histologic tissue diagnosis of PCLs.
Recruiting1 award N/A2 criteria

More about Jason Samarasena, MD

Clinical Trial Related4 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 1 Active Clinical Trial
Treatments Jason Samarasena, MD has experience with
  • EUS-FNA Alone
  • EUS-FNA Plus MFB
  • CM-4620 Injectable Emulsion Or CM-4620-IE
  • Placebo
Breakdown of trials Jason Samarasena, MD has run
Systemic Inflammatory Response Syndrome
Pancreatic Insufficiency

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Jason Samarasena, MD specialize in?
Is Jason Samarasena, MD currently recruiting for clinical trials?
Are there any treatments that Jason Samarasena, MD has studied deeply?
What is the best way to schedule an appointment with Jason Samarasena, MD?
What is the office address of Jason Samarasena, MD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security